BioCentury | Jul 11, 2015
Company News

Management tracks

...was VP of oncology for worldwide clinical trials and VP of global clinical R&D for Talon Therapeutics Inc....
BioCentury | Sep 9, 2013
Company News

Spectrum Pharmaceuticals sales and marketing update

...mg/m 2 administered over one hour. Spectrum gained the product through its July acquisition of Talon Therapeutics Inc....
BioCentury | Jul 22, 2013
Company News

Spectrum Pharmaceuticals, Talon Therapeutics deal

...with EGFR anti-cancer agents (see BioCentury, Aug. 13, 2012). Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Talon Therapeutics Inc....
BioCentury | May 20, 2013
Company News

Zosano management update

...Drug delivery Hired: Nandan Oza as COO, formerly VP of chemistry, manufacturing and controls at Talon Therapeutics Inc. WIR...
BioCentury | Jan 14, 2013
Company News

Talon Therapeutics cancer news

...Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR, Burnaby, B.C.) under a 2006 deal (see BioCentury, Aug. 13, 2012). Talon Therapeutics Inc....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Trokendi XR topiramate Epilepsy U.S. (tentative) Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Oxtellar XR oxcarbazepine Epilepsy U.S. Talon Therapeutics Inc....
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

...Johnson & Johnson (NYSE:JNJ) EC approves a subcutaneous formulation of Velcade bortezomib to treat MM Talon Therapeutics Inc....
BioCentury | Aug 20, 2012
Product Development

Clawing towards approval

...development at two companies, Marqibo vincristine sulfate received accelerated approval from FDA this month after Talon Therapeutics Inc....
...stock, milestones of up to $30.5 million in stock, plus royalties. Talon, then known as Hana Biosciences...
...NASDAQ:ENZN), Bridgewater, N.J. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Talon Therapeutics Inc....
BioCentury | Aug 13, 2012
Clinical News

Marqibo vincristine regulatory update

...designation in the U.S. for ALL and Orphan Drug designation in the EU for leukemia. Talon Therapeutics Inc....
BioCentury | Aug 13, 2012
Finance

Highlights of weekly biotech stock moves

...in patients previously treated with docetaxel. The agency last month granted the application Priority Review. Talon Therapeutics Inc....
Items per page:
1 - 10 of 139
BioCentury | Jul 11, 2015
Company News

Management tracks

...was VP of oncology for worldwide clinical trials and VP of global clinical R&D for Talon Therapeutics Inc....
BioCentury | Sep 9, 2013
Company News

Spectrum Pharmaceuticals sales and marketing update

...mg/m 2 administered over one hour. Spectrum gained the product through its July acquisition of Talon Therapeutics Inc....
BioCentury | Jul 22, 2013
Company News

Spectrum Pharmaceuticals, Talon Therapeutics deal

...with EGFR anti-cancer agents (see BioCentury, Aug. 13, 2012). Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Talon Therapeutics Inc....
BioCentury | May 20, 2013
Company News

Zosano management update

...Drug delivery Hired: Nandan Oza as COO, formerly VP of chemistry, manufacturing and controls at Talon Therapeutics Inc. WIR...
BioCentury | Jan 14, 2013
Company News

Talon Therapeutics cancer news

...Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR, Burnaby, B.C.) under a 2006 deal (see BioCentury, Aug. 13, 2012). Talon Therapeutics Inc....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Trokendi XR topiramate Epilepsy U.S. (tentative) Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Oxtellar XR oxcarbazepine Epilepsy U.S. Talon Therapeutics Inc....
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

...Johnson & Johnson (NYSE:JNJ) EC approves a subcutaneous formulation of Velcade bortezomib to treat MM Talon Therapeutics Inc....
BioCentury | Aug 20, 2012
Product Development

Clawing towards approval

...development at two companies, Marqibo vincristine sulfate received accelerated approval from FDA this month after Talon Therapeutics Inc....
...stock, milestones of up to $30.5 million in stock, plus royalties. Talon, then known as Hana Biosciences...
...NASDAQ:ENZN), Bridgewater, N.J. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Talon Therapeutics Inc....
BioCentury | Aug 13, 2012
Clinical News

Marqibo vincristine regulatory update

...designation in the U.S. for ALL and Orphan Drug designation in the EU for leukemia. Talon Therapeutics Inc....
BioCentury | Aug 13, 2012
Finance

Highlights of weekly biotech stock moves

...in patients previously treated with docetaxel. The agency last month granted the application Priority Review. Talon Therapeutics Inc....
Items per page:
1 - 10 of 139